drugset
drugset / Trial / NCT06371482

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

NCT06371482 ↗

Phase 2 Recruiting 58 enrolled Hebei Medical University Fourth Hospital
NaSingle-groupOpen-labelTreatment

Summary

This trial aims to assess efficacy and safety of durvalumab combined with chemoradiotherapy for limited stage small cell lung cancer.

Timeline

Start
2023-06-01
Primary completion
2024-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody 10 mg/kg Intravenous
Background Carboplatin Small molecule 5 unknown Intravenous
Background Carboplatin Small molecule 6 unknown Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Intravenous
Background Cisplatin Other / unclassified 80 mg/m2 Intravenous
Background Etoposide Small molecule 80 mg/m2 Intravenous
Background Etoposide Small molecule 100 mg/m2 Intravenous

Indications

small cell lung carcinoma